TUPEA11 DPP9 inhibitors: a novel class of drugs for clearance of HIV-1 infected cellsPoster exhibitionNovel treatment and prevention strategies
EPB0270 Effects of oral cannabinoids on systemic inflammation and viral reservoirs in people with HIV on antiretroviral therapy: results of the CTNPT 028 clinical trialE-posterOther strategies and therapies
LBEPB17 Analytical treatment interruption among African women and Peruvian men & transgender individuals with early ART initiation +/- VRC01 circulating at HIV acquisition: early observations of viral rebound & controlE-posterOther strategies and therapies
LBEPB18 Anti-PD-L1 antibody ASC22 in combination with chidamide potentiates HIV latency reversal and immune function from ART-suppressed individuals: a single center, single-arm, phase 2 studyE-posterOther strategies and therapies
LBEPB20 T-cell responses induced by HTI vaccines and vesatolimod correlate with improved control of HIV reboundE-posterOther strategies and therapies
TUPEB15 Ruxolitinib-mediated HIV-1 reservoir decay in A5336 phase 2a trialPoster exhibitionOther strategies and therapies
TUPEB16 Transformation of 3 current short-acting HIV drugs, tenofovir, lamivudine and dolutegravir (TLD) into a novel, all-in-one long-acting TLD 3-drug-combination in a single injectable dosage that produces extended pharmacokineticsPoster exhibitionOther strategies and therapies
TUPEB17 A biodegradable, subcutaneous implant delivery platform to treat HIV for up to 6 months in young childrenPoster exhibitionOther strategies and therapies
EPC0417 Met gender affirming care needs is associated with accessing HIV services among transgender people in a community-led clinic in Metro Manila, PhilippinesE-posterPopulation-specific interventions for HIV prevention
EPC0418 Comparing PrEP initiation rates among HIV-negative high-risk adolescents and young adults: a population-based prospective study in a high HIV prevalent district in South AfricaE-posterPopulation-specific interventions for HIV prevention
1021 - 1030 of 1427 items